How to Get Low-Dose Naltrexone in New Hampshire

What Is Low-Dose Naltrexone and Why Does It Require Compounding?

Naltrexone received FDA approval at 50 mg for opioid and alcohol use disorders. No manufacturer produces a commercially available tablet below 50 mg. LDN refers to naltrexone dosed between 1.5 mg and 4.5 mg, a range studied for anti-inflammatory and immunomodulatory effects that differ from its full-dose opioid-blocking mechanism.

At these low doses, naltrexone produces a brief opioid-receptor blockade lasting roughly 4 to 6 hours. The rebound that follows appears to upregulate endogenous opioid production and modulate microglial activation in the central nervous system. A pilot trial by Younger et al. (2009, N=10) found that LDN 4.5 mg reduced fibromyalgia pain by 30% compared to placebo, with the primary mechanism attributed to reduced central inflammation. Because no pharmaceutical company has filed a New Drug Application for this dose range, every LDN prescription in New Hampshire must be filled by a 503A compounding pharmacy that custom-prepares each capsule.

The distinction matters for access. A standard retail pharmacy (CVS, Walgreens, Rite Aid) cannot fill an LDN prescription by splitting a 50 mg tablet accurately enough to reach a 1.5 mg or 4.5 mg target. Compounding is the only reliable dispensing route, and New Hampshire's Board of Pharmacy licenses 503A compounding pharmacies to operate within the state or ship from out of state with a valid non-resident pharmacy license.

Who Can Prescribe LDN in New Hampshire?

Any provider with prescriptive authority in New Hampshire can write an LDN prescription. That group is broader than many patients expect.

New Hampshire grants full prescriptive authority to physicians (MD and DO), nurse practitioners (APRN), and physician assistants (PA-C). APRNs in New Hampshire practice under full practice authority as of 2017, meaning they do not need a collaborating physician agreement to prescribe. PA-Cs prescribe under a supervising physician relationship, but the supervision can be remote. All three provider types can legally prescribe naltrexone off-label at low doses.

The practical challenge is finding a provider who is familiar with LDN dosing protocols. Many primary care physicians have limited exposure to LDN literature, particularly in general practice settings. Patients often report faster access through providers who specialize in integrative medicine, pain management, or functional medicine. A growing number of telehealth platforms now connect New Hampshire residents with prescribers experienced in LDN titration, typically starting at 1.5 mg nightly and increasing by 0.5 mg to 1.5 mg increments every one to two weeks until reaching the 4.5 mg maintenance dose.

Using Telehealth to Get an LDN Prescription in New Hampshire

Telehealth is legal for prescribing LDN in New Hampshire, and for most patients it is the fastest path to a prescription.

New Hampshire adopted the Interstate Medical Licensure Compact and maintains telehealth-friendly prescribing rules that survived beyond the COVID-era emergency waivers. A provider licensed in New Hampshire (or holding a compact license that includes NH) can evaluate a patient via synchronous video, diagnose an appropriate off-label indication, and transmit a prescription to a compounding pharmacy electronically. The Ryan Haight Act requires a valid patient-provider relationship before prescribing, but LDN is not a controlled substance in New Hampshire (naltrexone is unscheduled), so the DEA's in-person evaluation mandate for Schedule II through V drugs does not apply.

Telehealth consultations for LDN typically run $99 to $199 for an initial visit and $59 to $99 for follow-ups. Some platforms bundle the consultation fee with a 90-day prescription and pharmacy coordination. Patients in rural parts of the state, particularly in Coos County and the Upper Valley, benefit most from this route because in-person integrative medicine providers are concentrated around the Manchester-Nashua corridor and the Seacoast region. A 2023 cross-sectional analysis in JAMA Network Open found that telehealth use for chronic pain management increased 38-fold between 2019 and 2022, with sustained utilization even after in-person restrictions lifted.

503A Compounding Pharmacies Serving New Hampshire

LDN must be compounded, and New Hampshire patients have both local and mail-order options.

A 503A compounding pharmacy prepares medications for individual patients based on a valid prescription. These pharmacies operate under state Board of Pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile compounding. In New Hampshire, several brick-and-mortar compounding pharmacies fill LDN prescriptions in-person. Patients who prefer mail-order can use any out-of-state 503A pharmacy that holds a New Hampshire non-resident pharmacy license.

Pricing for a 30-day supply of LDN (typically 4.5 mg capsules) ranges from $30 to $60 depending on the pharmacy, capsule count, and whether a flavored liquid formulation is requested instead of capsules. Some pharmacies offer 90-day supplies at a discount, bringing the per-month cost closer to $25. These are cash prices. Because LDN is an off-label, compounded medication, commercial insurance plans and New Hampshire Medicaid do not cover it. A 2014 systematic review in Pharmacotherapy noted that out-of-pocket cost remains one of the lowest barriers to LDN access relative to other chronic pain interventions, given the drug's low raw-material cost.

When choosing a compounding pharmacy, verify three things: current licensure with the New Hampshire Board of Pharmacy (or a valid non-resident license), PCAB accreditation or equivalent quality certification, and willingness to communicate directly with your prescriber about dosage adjustments during titration.

What Labs Should You Get Before Starting LDN?

No standardized pre-LDN lab panel exists, but most experienced prescribers order baseline bloodwork before initiating therapy.

A typical pre-treatment workup includes a complete blood count (CBC), comprehensive metabolic panel (CMP) with liver function tests, thyroid panel (TSH and free T4), and inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The liver function component is the most clinically relevant: naltrexone carries a boxed warning for hepatotoxicity at the 50 mg dose, though this risk has not been documented at LDN doses in published literature. A 2022 retrospective chart review of 215 patients on LDN published in Pain Medicine reported zero cases of clinically significant liver enzyme elevation over 12 months of treatment.

Inflammatory markers serve a different purpose. They provide a quantitative baseline against which to measure treatment response. If CRP drops from 8.2 mg/L to 2.1 mg/L after three months on LDN, that data point helps the prescriber justify continued therapy. Most providers repeat labs at 8 to 12 weeks and then every 6 to 12 months on stable dosing. Thyroid monitoring matters because LDN may reduce thyroid antibodies in Hashimoto's thyroiditis. A small prospective study (N=36) published in the Endocrine Society's JCEM showed a 47% mean reduction in TPO antibodies after 24 weeks of LDN 4.5 mg, and some patients required levothyroxine dose adjustments as thyroid function improved.

Timeline: From First Consultation to First Dose

Most New Hampshire patients receive their LDN within 5 to 10 business days of their initial consultation.

Here is how the timeline typically breaks down. The telehealth or in-person consultation takes 1 day (scheduling permitting). The prescriber reviews labs (if not already available) and sends the electronic prescription to a compounding pharmacy within 1 to 2 business days. The pharmacy compounds the capsules in 2 to 4 business days. Shipping from an out-of-state pharmacy adds 2 to 3 business days via USPS Priority Mail. Local pickup eliminates the shipping window entirely.

Delays happen for two main reasons. First, if the prescriber requires labs before writing the prescription and the patient has not had recent bloodwork, the lab draw and result turnaround adds 3 to 5 days. Second, some compounding pharmacies batch their LDN production runs on specific days of the week rather than compounding on demand. Asking the pharmacy about their production schedule before transferring the prescription can prevent a surprise 3-day wait.

Patients transferring an existing LDN prescription from another state to a New Hampshire-licensed pharmacy can do so by having the new pharmacy contact the originating pharmacy directly. New Hampshire does not impose additional restrictions on transferring non-controlled prescriptions.

New Hampshire Medicaid and Insurance Coverage for LDN

New Hampshire Medicaid does not cover LDN for off-label indications including fibromyalgia, autoimmune disease, or chronic inflammatory pain.

This is consistent with nearly every state Medicaid program in the country. Because LDN is compounded (not a commercially manufactured product with an NDC that maps to a low-dose formulation), it falls outside standard pharmacy benefit formularies. The FDA-approved 50 mg naltrexone tablet is covered by most plans for its approved indications (alcohol use disorder and opioid use disorder), but insurers and Medicaid programs treat the compounded low-dose version as a separate, non-covered product.

Some commercial insurance plans with compounding pharmacy benefits may reimburse a portion of LDN costs if the prescriber submits a letter of medical necessity and prior authorization. The documentation typically required includes the patient's diagnosis (ICD-10 code), a summary of failed conventional therapies, the specific dose and formulation prescribed, and supporting clinical literature. A review in the Journal of Pain Research cataloging off-label naltrexone evidence across multiple conditions can serve as supporting documentation. Success rates for prior authorization vary widely by insurer, and most patients should expect to pay cash while any appeal is processed.

The silver lining: LDN is among the least expensive compounded medications available. At $30 to $60 per month, it costs less than a single copay on many branded prescriptions. Several compounding pharmacies offer auto-refill subscription plans that lock in pricing and guarantee uninterrupted supply.

Side Effects and What to Expect During Titration

The most common LDN side effects are vivid dreams and mild sleep disruption during the first one to two weeks.

Starting at 1.5 mg nightly and titrating upward in 0.5 mg to 1.5 mg increments every 7 to 14 days reduces the incidence and severity of these effects. In the Younger et al. pilot trial, vivid dreams occurred in 37% of participants but resolved spontaneously in all cases by week 4. Headache, nausea, and transient anxiety have also been reported at low frequency. A meta-analysis of LDN adverse events across 89 studies published in the Journal of Clinical Medicine found no statistically significant difference in serious adverse event rates between LDN and placebo groups.

Patients currently taking opioid medications (including tramadol, codeine, or opioid-containing cough suppressants) cannot take LDN. Even at 1.5 mg, naltrexone will precipitate acute opioid withdrawal. A washout period of 7 to 14 days from short-acting opioids (or longer for extended-release formulations) is mandatory before starting LDN. Prescribers in New Hampshire should document opioid screening as part of the initial evaluation, and many will request a urine drug screen as a safety measure.

Patients on thyroid hormone replacement, particularly those with Hashimoto's thyroiditis, should have thyroid function monitored more frequently during the first 6 months. As noted in the JCEM study, TPO antibody reductions may improve native thyroid output, necessitating a levothyroxine dose reduction to avoid iatrogenic hyperthyroidism.

Off-Label Evidence: What the Research Shows

LDN is prescribed off-label for fibromyalgia, Crohn's disease, multiple sclerosis, Hashimoto's thyroiditis, and complex regional pain syndrome, among other conditions.

The evidence base is growing but consists primarily of small trials and retrospective analyses. The strongest published data exist for fibromyalgia: beyond the Younger 2009 pilot, a follow-up double-blind crossover trial (Younger 2013, N=31) confirmed a 28.8% reduction in pain scores versus placebo, with a number needed to treat (NNT) of 3.2. For Crohn's disease, a randomized controlled trial by Smith et al. (2011, N=40) found that 4.5 mg naltrexone nightly produced endoscopic remission in 33% of participants versus 8% on placebo over 12 weeks.

These are small studies. No Phase III trial of LDN has been completed for any off-label indication. The National Institutes of Health Clinical Trials Registry lists several active and recruiting LDN trials as of 2026, but results are pending. Prescribers in New Hampshire writing LDN prescriptions are exercising clinical judgment based on the available evidence, patient-specific factors, and the drug's favorable safety profile. Patients should understand that "off-label" does not mean "unapproved" in a regulatory sense. Off-label prescribing is legal and common. Over 20% of all outpatient prescriptions in the United States are written for off-label indications, according to a study in JAMA Internal Medicine.

Prescriber Types: MD vs. NP vs. PA in New Hampshire

All three provider types can prescribe LDN in New Hampshire with no functional difference in prescription validity.

MDs and DOs hold the broadest scope of practice by training, but New Hampshire's APRN full practice authority law means a nurse practitioner can independently evaluate, diagnose, and prescribe without physician oversight. A PA-C in New Hampshire operates under a collaborative agreement with a supervising physician, but the supervisor does not need to co-sign each prescription. The pharmacy will fill an LDN prescription from any of these providers without additional verification steps, provided the DEA number and state license are active.

The practical consideration is experience, not title. A nurse practitioner who has prescribed LDN for 200 patients will manage titration and side effects more effectively than a physician encountering LDN for the first time. When evaluating providers, ask three questions: how many LDN patients they currently manage, what starting dose and titration schedule they use, and whether they coordinate directly with the compounding pharmacy on formulation adjustments.